Roche's Glofitamab treatment relapsed/resusive NHL showed strong results

Roche recently released the latest data from patients with CD20xCD3 T-cell binding to the dual-specific antibody glofitamab (formerly CD20-TCB) to treat patients with relapsed or incurable (R/R) non-Hodgkin's lymphoma (NHL) at the 25th annual meeting of the European Society of Hematology (EHA).The latest results from the Phase I dose increment NP30179 study (NCT03075696) show that 12 cycles (21 days/cycle) of glofitamab fixed treatment showed lasting total remission (CR) in patients who had previously received a median of 3 treatment options for over-pretreatment (heavily pre-treated)."Non-Hodgkin's lymphoma (NHL), such as diffuse large B-cell lymphoma (DLBCL), can pose considerable therapeutic challenges, particularly in cases involving multiple recurrences," said Dr. Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development. We are encouraged by these early results, which support glofitamab's potential for patients who have failed multiple previous treatments and are in urgent need of new treatment options. Updatedfrom ≥0.6mg and ≥10mg queues show high mitigation rates in each NHL subgroup:
- in ≥ In the 0.6mg queue, the researchers assessed a CR rate of 30.9% (38/123) and a total remission rate (ORR) of 45.5% (56/123) in invasive NHL patients. In patients with inert NHL, the researchers assessed a CR rate of 52.2% (12/23) and a total remission rate (ORR) of 65.2% (15/23).

- In ≥ 10mg of invasive NHL patients, the researchers assessed a CR rate of 34.1% (29/85) and a total remission rate (ORR) of 49.4% (42/85). In patients with inert NHL, the researchers assessed a CR rate of 50.0% (9/18) and a total remission rate (ORR) of 66.7% (12/18).

-CR shows persistence, with 72.7 percent (24/33) of patients with CR in the ≥0.6 mg queue and 81.8 percent (9/11) of inert NHL patients maintaining CR at the data cut-off date (April 17, 2020). The medium follow-up was 10.2 months, and the CR mid-duration of the 2 groups was not reached.

- glofitamab's security fits its mechanism. Common adverse events in more than 15% of the subjects in the ≥0.6 mg queue (n=156) were cytokine release syndrome (CRS; n=88,56.4%), and reduction of neutral granulocytes (n=) 48,30.8%), fever (n=47,30.1%), anemia (n=35,22.4%) and plateplate reduction (n=26,16.7%). Most CRS events are low-level (1-2), related to the first cycle, and are controllable.Glofitamab is a research CD20xCD3 T cell that binds to dual-specific antibodies and is designed to target CD20 and T cell surfaces of B cells. This dual target activates and redirects the patient's existing T cells, eliminating the target B cells by binding B cells and releasing cytotoxic proteins to B cells. Glofitamab has a new "2:1" structure and is designed to have two Fab zones combining CD20 and one Fab zone combining CD3.Roche is currently advancing a powerful clinical development project at Glofitamab that uses this molecule as a monotherapy and in combination with other drugs to treat CD20-positive B-cell non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma (DLBCL) and fiery lymphoma (FL)) and other blood cancers.Among them, joint drug use includes the investigation of glofitamab and Polivy (polatuzumab vedotin), Tecentriq (Atozolizumab), Mab Theera/Rituxan (rituxima) in the NHL and other blood cancers b) A joint drug use study with Gazyva/Gazyvaro (obinutuzumab) involving a variety of treatment environments and tumor types, including early treatment, to determine the circumstances under which glofitamab can provide therapeutic benefits compared to current treatment options. (
Bio Valley
)